ArticleHepatology international2025
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma.
Article in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of prognostic nutritional index in patients with hepatocellular carcinoma undergoing hepatectomy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Preoperative RDW-Albumin Ratio as a Prognostic Biomarker in Gastric Cancer Surgery.Cancer medicine · 2026Article
- Chronic stress drives gastric cancer lymph node metastasis via NETosis through a feedforward ACh-NGF axis-mediated PKC-γ/STAT3 pathway.Oncogene · 2026Article
- Enhancing the prognostic value of inflammatory markers in hepatocellular carcinoma: a thoughtful discussion.Hepatology international · 2026Article
- Development and validation of a biopsy-based model using tumor-associated neutrophils to predict neoadjuvant chemotherapy response in osteosarcoma: a large single-center retrospective cohort study.Journal of bone oncology · 2026Article
- Multi-omics integration model of exosome metabolomics and PD-1/PD-L1 expression for early prediction of immunotherapy efficacy in advanced liver cancer.Scientific reports · 2026Article
- Prediction of the efficacy after the first transarterial chemoembolization in hepatocellular carcinoma using CT radiomics combined with inflammatory composite indicators.Frontiers in medicine · 2026Article
- FT3 Levels and Systemic Inflammation: Evidence From a Population-Based NHANES Analysis.Mediators of inflammation · 2026Article
- Development and Validation of a LASSO-RF-Cox-Derived Nomogram Incorporating Inflammatory Markers to Predict Long-Term Survival in Early-Stage Hepatocellular Carcinoma After Microwave Ablation.Journal of hepatocellular carcinoma · 2026Article
- Inflammation in hepatocellular carcinoma progression: a "Single Wick, dual interwoven strands" regulatory framework.Frontiers in immunology · 2026Review
- Prediction of tumor progression in intermediate and advanced hepatocellular carcinoma undergoing TACE combined with targeted immunotherapy.Frontiers in oncology · 2026Article
- Prognostic model for predicting recurrence-free survival in HBV-related hepatocellular carcinoma patients after combined treatment: a multicenter study.Frontiers in oncology · 2026Article
- Constructing and validating a prognostic prediction nomogram model for hepatocellular carcinoma patients following high-intensity focused ultrasound treatment.Frontiers in oncology · 2026Article
- Multicenter Validation of a RAR-Based Nomogram for Predicting Postoperative Progression in HBV-Related Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Lactate Dehydrogenase as a Potential Mediator Between Immature Granulocytes and Tumor Burden in Breast Cancer.Journal of inflammation research · 2026Article
- The predictive value of dynamic changes in neutrophil-to-lymphocyte ratio for the prognosis of hepatocellular carcinoma patients treated with transarterial chemoembolization.Discover oncology · 2025Article
- A non-invasive nomogram for the prediction of poor prognosis of hepatocellular carcinoma based on the novel marker Interleukin-41.BMC cancer · 2025Article
- Association Between the C-Reactive Protein-Albumin-Lymphocyte Index and Endometriosis: Insights from the 1999-2006 National Health and Nutrition Examination Survey.International journal of women's health · 2025Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background/purpose of the studyWe aimed to evaluate the performance of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and their combination (combined NLR-PLR, CNP) in predicting overall survival (OS) and recurrence-free survival (RFS) in a large cohort of unselected hepatocellular carcinoma (HCC) patients.
methodsTraining and validation cohort data were retrieved from the Italian Liver Cancer (ITA.LI.CA) database. The optimal cut-offs of NLR and PLR were calculated according to the multivariable fractional polynomial and the minimum p value method. The continuous effect and best cut-off categories of NLR and PLR were analyzed using multivariable Cox regression analysis. A shrinkage procedure adjusted over-fitting hazard ratio (HR) estimates of best cut-off categories. C-statistic and integrated discrimination improvement (IDI) were calculated to evaluate the discrimination properties of the biomarkers when added to clinical survival models.
results2,286 patients were split into training (n = 1,043) and validation (n = 1,243) cohorts. The optimal cut-offs for NLR and PLR were 1.45 and 188, respectively. NLR (HR 1.58, 95% CI 1.11-2.28, p = 0.014) and PLR (HR 1.79, 95% CI 1.11-2.90, p = 0.018) were independent predictors of OS. When incorporated into a clinical prognostic model that includes age, alpha-fetoprotein (AFP), the CHILD-Pugh score, and the Barcelona Clinic Liver Cancer (BCLC) staging system, CNP had a significant incremental value in predicting OS (IDI 1.3%, p = 0.04). Data were confirmed in the validation cohort. Neither NLR nor PLR significantly predicted RFS in the training cohort.
conclusionsNLR, PLR, and CNP independently predicted shorter OS in HCC patients. The addition of CNP to the survival prediction model significantly improved the model's accuracy in predicting OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.